Scancell’s dilemma delayed
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
No PRAME encore for Immatics
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
The markets stress over Nuvectis
NXP800 yields neither severe thrombocytopenia, nor any responses.
ASH 2024 preview – more challenges to the BTK order
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
Heartache for Syndax
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
ASH 2024 preview – multiple myeloma in focus
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
